SGMO News Alert Sangamo Biosciences (SGMO) 14.20 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sangamo Biosciences (SGMO) 14.20 $SGMO

Sangamo Biosciences Up 26.4% Since SmarTrend Uptrend Call (SGMO)
Comtex SmarTrend(R) - Fri Dec 19, 9:39AM CST
SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on October 28th, 2014 at $12.13. In approximately 2 months, Sangamo Biosciences has returned 26.35% as of today's recent price of $15.32.
SGMO: 14.20 (+0.14)

2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses
at The Street - Thu Dec 18, 8:35AM CST
Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.
BLUE: 88.76 (+3.23), VRTX: 115.15 (+1.40), GILD: 91.29 (+1.84), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), SGMO: 14.20 (+0.14)

Investors bagging some profits on BLUE, SGMO
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:40AM CST

BLUE: 88.76 (+3.23), SGMO: 14.20 (+0.14)

Lysosomal Storage Disorder - Pipeline Review, H1 2014
M2 - Mon Dec 15, 4:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/9z3fm9/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Lysosomal Storage Disorder - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Lysosomal Storage Disorder pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Sangamo BioSciences, Inc. - Neuralstem, Inc. - Amicus Therapeutics, Inc. - Cytomedix, Inc. - AngioChem Inc. - Zymenex A/S - Synageva BioPharma Corp. - Fate Therapeutics, Inc. - to-BBB technologies BV - REGiMMUNE Corporation - biOasis Technologies Inc. - ArmaGen Technologies, Inc. - Orphazyme ApS - Oxyrane Belgium NV - Ultragenyx Pharmaceutical Inc. - Minoryx Therapeutics s.l. For more information visit http://www.researchandmarkets.com/research/9z...al_storage
FATE: 4.90 (+0.23), GEVA: 89.72 (-0.02), SGMO: 14.20 (+0.14), FOLD: 7.94 (+0.06), CUR: 2.70 (+0.07)

Intermittent Claudication - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/59bmx9/intermittent) has announced the addition of the "Intermittent Claudication - Pipeline Review, H2 2013" report to their offering. 'Intermittent Claudication - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Intermittent Claudication, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intermittent Claudication. Intermittent Claudication - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Intermittent Claudication. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Intermittent Claudication pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Nissan Chemical Industries, Ltd. - Sangamo BioSciences, Inc. - Rigel Pharmaceuticals, Inc. - Sigma-Tau S.p.A. - Cytokinetics, Incorporated - Cytomedix, Inc. - Pluristem Therapeutics Inc. - LTT Bio-Pharma Co., Ltd. - Taisho Toyama Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/59...termittent
CYTK: 5.87 (+0.35), PSTI: 2.46 (unch), SGMO: 14.20 (+0.14), RIGL: 2.22 (+0.02)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 4:39PM CST

ENPH: 14.38 (-0.02), ATTO: 9.94 (-0.16), TVIX: 2.29 (-0.02), GGB: 3.56 (-0.08), ARRS: 30.17 (+0.30), DGAZ: 7.23 (+0.74), SGMO: 14.20 (+0.14), CCXI: 6.64 (-0.04), ILF: 31.85 (+0.05), GSAT: 2.97 (+0.03)

Shares of SGMO Up 16.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Dec 12, 9:14AM CST
SmarTrend identified an Uptrend for Sangamo Biosciences (NASDAQ:SGMO) on October 28th, 2014 at $12.13. In approximately 2 month, Sangamo Biosciences has returned 16.16% as of today's recent price of $14.09.
SGMO: 14.20 (+0.14)

Sangamo Biosciences (SGMO) Jumps: Stock Rises 7.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 8:46AM CST
Sangamo Biosciences (SGMO) was a big mover last session, with shares rising over 7%.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), SGMO: 14.20 (+0.14), AFFX: 9.80 (+0.05)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 11:45AM CST

SD: 2.02 (-0.04), FRO: 2.43 (-0.01), ABCO: 49.30 (-0.58), ZAZA: 3.20 (+0.70), JMEI: 15.09 (+0.21), SGMO: 14.20 (+0.14), TGTX: 16.03 (+0.33), MEI: 36.68 (+0.62), WLT: 1.45 (-0.02), NSPR: 0.70 (-0.02), VII: 1.83 (+0.38), CVTI: 26.18 (+0.05), MEIP: 3.90 (+0.11), ALDR: 25.67 (+0.43), CALA: 22.33 (+1.16), CGG: 6.19 (-0.05), SPP: 1.63 (+0.18), DSCO: 1.17 (+0.01), KPTI: 37.78 (+1.28), HBOS: 25.74 (+0.06)

Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014
M2 - Wed Dec 10, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/vv3g4v/alpha) has announced the addition of the "Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alpha- Antitrypsin Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alpha- Antitrypsin Deficiency and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Alpha- Antitrypsin Deficiency - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Applied Genetic Technologies Corporation - Arrowhead Research Corporation - Carolus Therapeutics - Cevec Pharmaceuticals - Dicerna Pharmaceuticals - Grifols - iBio - International Stem Cell Corporation - Intrexon Corporation - Kamada - OrphageniX - Polyphor - rEVO Biologics - Sangamo BioSciences For more information visit http://www.researchandmarkets.com/research/vv3g4v/alpha
DRNA: 16.23 (-0.23), ARWR: 6.35 (+0.07), SGMO: 14.20 (+0.14), XON: 26.19 (+0.67), RBIO: ()

Sangamo rides bluebird's wave
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 2:45PM CST

BLUE: 88.76 (+3.23), SGMO: 14.20 (+0.14)

Sangamo BioSciences Presents New Data at American Society of Hematology Meeting Demonstrating Broad Application of ZFN Mediated Genome-Editing Approach to Therapeutics for Hemophilia and Lysosomal Storage Disorders
PR Newswire - Mon Dec 08, 6:00AM CST
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new preclinical data from its proprietary programs for the treatment of lysosomal storage disorders (LSD) and Shire-partnered hemophilia program. These studies demonstrate the broad applicability of Sangamo's In Vivo Protein Replacement Platform (IVPRP) for the potentially curative treatment of such diseases, and were presented at the 56th Annual Meeting of the American Society of Hematology (ASH) held in San Francisco from December 5 to 9, 2014.
SGMO: 14.20 (+0.14)

Calithera Biosciences hires H. Ward Wolff to board
M2 - Wed Dec 03, 7:06AM CST
Pharmaceutical company Calithera Biosciences (NasdaqGS:CALA) reported on Tuesday the addition of H. Ward Wolff to its board of directors as well as chair of its Audit Committee.
PTLA: 28.35 (+0.21), CALA: 22.33 (+1.16), SGMO: 14.20 (+0.14)

Calithera Biosciences Appoints H. Ward Wolff to Board of Directors
GlobeNewswire - Tue Dec 02, 4:00PM CST
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced today the appointment of H. Ward Wolff to the company's Board of Directors, where he will chair the company's Audit Committee. Mr. Wolff is currently Executive Vice President and Chief Financial Officer of Sangamo BioSciences, Inc.
CALA: 22.33 (+1.16), SGMO: 14.20 (+0.14)

Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms
PR Newswire - Wed Nov 19, 6:00AM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that positive preclinical data from its joint program with Shire plc, to develop a novel ZFP Therapeutic® approach to Huntington's disease (HD), will be presented at the 2014 Annual Meeting of the Society for Neuroscience. The data were generated by Sangamo scientists and the CHDI Foundation. Neuroscience 2014, which is the world's largest forum for neuroscientists to present their research, is being held in Washington D.C. from November 15-19, 2014.
SHPG: 209.29 (+0.07), SGMO: 14.20 (+0.14)

Sangamo BioSciences Announces Presentation at the 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 18, 3:02PM CST
Sangamo BioSciences, Inc. (Nasdaq:SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeuticdevelopment programs and an overview of the company's business strategy at 8:00 am ET on Tuesday, December 2, 2014, at the 26th Annual Piper Jaffray Healthcare Conference in New York.
SGMO: 14.20 (+0.14)

Insider Trading Alert - CCOI, CRM And SGMO Traded By Insiders
at The Street - Fri Nov 14, 10:49AM CST
Stocks with insider trader activity include CCOI, CRM and SGMO
CCOI: 34.97 (-0.06), SGMO: 14.20 (+0.14), CRM: 60.33 (-0.17)

Earnings Look Back: Sangamo Biosciences Is Up 9.5% Since Reporting Quarterly Results 2 Weeks Ago (SGMO)
Comtex SmarTrend(R) - Mon Nov 10, 12:49PM CST
19 days ago, on October 22nd, 2014, Sangamo Biosciences (NASDAQ:SGMO) reported its earnings. Analysts, on average, expected a loss of $0.14 per share on sales of $8.5 million. Sangamo Biosciences actually reported a loss of $0.11 per share on sales of $12.4 million, beating EPS estimates by $0.03 and beating revenue estimates by $4.0 million. Shares of Sangamo Biosciences have climbed from $10.34 to $11.32, representing a gain of 9.5% since the company reported earnings 19 days ago.
SGMO: 14.20 (+0.14)

Sangamo BioSciences President and CEO Edward Lanphier to Serve as Chairman of the Alliance for Regenerative Medicine
PR Newswire - Mon Nov 10, 8:05AM CST
Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that Edward Lanphier, the Company's president and CEO, has been elected to serve as the next Chairman of the Alliance for Regenerative Medicine (ARM). Washington, DC-based ARM is an international organization that represents and supports industry, clinical institutions, patient advocates and other stakeholders in the development of safe and effective gene and cell therapies. Mr. Lanphier succeeds Geoff MacKay, president and CEO of Organogenesis Inc., who will complete his two-year term as chairman on December 31, 2014.
SGMO: 14.20 (+0.14)

The Alliance for Regenerative Medicine Elects Edward Lanphier as Chairman, Welcomes New Officers and Executive Committee Members
GlobeNewswire - Mon Nov 10, 8:04AM CST
via PRWEB - The Alliance for Regenerative Medicine (ARM), the international organization representing the regenerative medicine and advanced therapies community, announces the election of Edward Lanphier, Founder, President and Chief Executive Officer (CEO) of Sangamo BioSciences (NASDAQ: SGMO), as its next Chairman. Robert Preti, Ph.D., Co-founder, President and Chief Scientific Officer (CSO) of Progenitor Cell Therapy (PCT) and CSO of NeoStem, has been named Vice-Chairman. Claudia Zylberberg, Ph.D., CEO of Akron Biotech, was elected as Treasurer and Phil Vanek, Ph.D., General Manager Cell BioProcessing at GE Healthcare, was elected Secretary. Mr. Lanphier will replace Geoff MacKay, President and CEO of Organogenesis Inc., who will complete his two-year term as Chairman on December 31, 2014.
SGMO: 14.20 (+0.14)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 107

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 54

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
Branch's Fast 500 Rank Signals Payroll Platform Reach

Updated Category News Views 118

Six straight appearances on Deloitte's Fast 500 is not random confetti; it says Branch has kept finding customers while plenty of fintech outfits were busy shrinking their ambitions. The Tampa-based workforce-payments company landed at No. 146 in the 2026 ranking, which measures fiscal-year revenue growth from 2022 through 2025. That is a respectable showing in a list...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 78

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 58

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading

Top 5 Most Recently Viewed Articles

Lido Staked Ether Experiences Significant Price Fluctuations

Updated Category News Views 50

The Recent Surge in Lido Staked Ether Lido Staked Ether has recently recorded a notable price increase of 3.0% in just the last 24 hours, now trading at $2,344.75. This rise seems to go against its trend over the past week, during which time the asset experienced a slight decline of 1.0%, falling from $2,333.90. The cryptocurrency has impressive highs, having reached an...

Continue Reading
Stella Artois Showcases Friendship with Super Bowl Ad Featuring Icons

Updated Category News Views 665

Stella Artois Presents an Iconic Super Bowl LIX Ad This year, Stella Artois crafts a memorable advertisement for Super Bowl LIX, showcasing the significance of connection through everyday moments. The campaign, titled 'For Moments Worth More,' aims to highlight how the simple pleasures in life can be elevated with the right company and a refreshing Stella Artois lager....

Continue Reading
Glucotrack Appoints New VP to Bolster Regulatory Strategy

Updated Category News Views 229

Glucotrack Welcomes Ted Williams as VP of Regulatory Affairs Glucotrack, Inc. is proud to announce the addition of Ted Williams as the new Vice President of Regulatory Affairs. This strategic move marks a significant step for the company as it continues to innovate and develop solutions for individuals managing diabetes. With nearly 25 years in the industry, Williams...

Continue Reading
Landstar System's Special Dividend Announcement for Shareholders

Updated Category News Views 156

Landstar System, Inc. Declares Special Cash Dividend Recently, Landstar System, Inc. (NASDAQ: LSTR) made headlines with an exciting announcement: a special one-time cash dividend of $2.00 per share. This decision, declared by the Board of Directors on a recent date, reflects the company's robust financial health and commitment to returning value to its shareholders....

Continue Reading
Market Insights: Economic Indicators and Trends to Watch

Updated Category News Views 276

Key Economic Indicators to Watch As we navigate through the current trading landscape, several economic indicators and events are set to shape the market narrative. Understanding these factors is crucial for informed trading decisions. Upcoming Economic Releases Starting the week, we have some pivotal economic releases lined up: Monday's Highlights The week begins with...

Continue Reading